CLOV Clover Health

NASDAQ
$4.23

Clover Health (CLOV) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal Bearish Selling ran elevated versus CLOV's own trailing one-year pace, with 88% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 6 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
4
6 transactions
Purchases
$0
0 shares
Sales
$1.6M
341,210 shares
Net activity
-$1.6M
purchases less sales

How much of that selling was preplanned? 88% planned / 12% discretionary

10b5-1 plan sales $1.4M 2 transactions · 301,921 shares
Discretionary sales $195.0K 4 transactions · 39,289 shares

Largest single sale: $1.4M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Reynoso Jamie L. CEO, Medicare Advantage Sell 10b5-1 1,921 $4.56 $8.8K 2,803,446 −0.1% of holding
OLDAKOWSKI JOSEPH FRANK VP OF FINANCE AND CONTROLLER Sell 3,170 $4.64 $14.7K 275,897 −1.1% of holding
Wai Conrad CEO, Counterpart Health Sell 10b5-1 300,000 $4.72 $1.4M 1,170,056 −20.4% of holding
Reynoso Jamie L. CEO, Medicare Advantage Sell 9,273 $4.78 $44.3K 2,805,367 −0.3% of holding
Soares Karen Chief Legal Officer Sell 6,846 $4.78 $32.7K 1,607,371 −0.4% of holding
OLDAKOWSKI JOSEPH FRANK VP OF FINANCE AND CONTROLLER Sell 20,000 $5.16 $103.2K 279,067 −6.7% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.